



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/277,789	10/20/2011	Robert A. Ashley	512-53 DIV/CON II	4179

23869 7590 05/14/2012
HOFFMANN & BARON, LLP
6900 JERICHO TURNPIKE
SYOSSET, NY 11791

EXAMINER

TRAN, SUSAN T

ART UNIT PAPER NUMBER

1615

MAIL DATE DELIVERY MODE

05/14/2012

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 13/277,789	Applicant(s) ASHLEY, ROBERT A.	
	Examiner SUSAN TRAN	Art Unit 1615	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) An election was made by the applicant in response to a restriction requirement set forth during the interview on _____; the restriction requirement and election have been incorporated into this action.
- 4) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 5) Claim(s) 21-40 is/are pending in the application.
5a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 6) Claim(s) _____ is/are allowed.
- 7) Claim(s) 21-40 is/are rejected.
- 8) Claim(s) _____ is/are objected to.
- 9) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 10) The specification is objected to by the Examiner.
- 11) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 12) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. _____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 02/01/12.
- 4) Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application
- 6) Other: _____.

DETAILED ACTION

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 21, 23, 25-28, 30, 32-35 and 38-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Perricone US 6,365,623, in view of Pflugfelder et al. US 6,455,583.

Perricone teaches a method for the treatment of pustule and papule. The method comprises orally administering an antibiotic compound. See column 5, lines 40-45; column 6, lines 20-24; and column 8, lines 24-29.

Perricone does not expressly teach the claimed amount of antibiotic compound, as well as the claimed antibiotic such as doxycycline.

Pflugfelder teaches a method for treating conditions associated with rosacea. The method comprises orally administering a tetracycline compound in a sub-antimicrobial amount that ranges from about 20% to about 80% of the normal antibiotic therapeutic dose of the particular tetracycline compound. See abstract; column 4, lines 1-10; and column 5, lines 1-12. Tetracycline compound includes doxycycline is found in column 6, line 5; and claim 3.

Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to optimize the method of Perricone to administer antibiotic

compound in a sub-antimicrobial amount in view of the teachings of Pflugfelder. This is because: 1) Pflugfelder teaches the use of an antibiotic compound for the treatment of rosacea related conditions is known in the art; 2) Pflugfelder teaches that long term administration of antibiotic compound in a sub-antimicrobial amount will minimized tetracycline advert side-effects such as nausea, vomiting, diarrhea, and epigastric pain (column 1, lines 48-63); and 3) Perricone teaches the desirability for administering antibiotic compound in a lower dosage amount to eliminate advert side-effect such as nausea, GI upset, yeast infection, and interactions with other medication (column 8, lines 30-40).

Claims 24, 25, 31, 32, 37 and 38 are rejected under 35 U.S.C. 103(a) as being unpatentable over Perricone US 6,365,623, in view of Pflugfelder et al. US 6,455,583 and Sheth et al. US 5,300,304.

Perricone is relied upon for the reasons stated above. The reference is silent with respect to the once-a-day sustained release dosage.

Sheth teaches a pulsatile once-a-day dosage form of a non-toxic acid tetracycline compound for the treatment of acne. See abstract; columns 5-6; and claims.

Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to optimize the composition of Perricone to include a once-a-day antibiotic composition because Sheth teaches an antibiotic once-a-day dosage form is known in the art.

Claims 22, 29 and 36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Perricone US 6,365,623, in view of Pflugfelder et al. US 6,455,583 and Heesch US 2002/0165220 A1.

Perricone is relied upon for the reasons stated above. Perricone does not teach the hyclate salt of doxycycline.

Heesch teaches a tetracycline compound useful for the treatment of acne includes doxycycline. Heesch further teaches that doxycycline hyclate exhibits better advantage over the doxycycline compound. See abstract; paragraphs 0093-0094 and claims.

Thus, it would have been obvious to one of ordinary skill in the art at the time the invention was made to optimize the composition of Perricone to include the hyclate salt of the antibiotic compound in view of the teachings of Heesch. This is because doxycycline monohydrate (hyclate) provides lower dosage requirement, and because Perricone teaches the desirability for lower antibiotic dosage.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSAN TRAN whose telephone number is (571)272-0606. The examiner can normally be reached on M-F 8:30 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.